Unique characteristics of CpG island methylator phenotype (CIMP) in a Chinese population with colorectal cancer

BMC Gastroenterology

Table 3 Sensitivity and specificity of each marker for determination of CIMP-high

Marker	Total no.	CIMP-1 (≥4/5)		CIMP-2 (≥3/5)		CIMP-3 (≥5/8)
Marker	Total no.	Positive (sensitivity)^a	Negative (specificity)^b	Positive (sensitivity) ^a	Negative (specificity) ^b	Positive (sensitivity) ^a	Negative (specificity) ^b
	401	34 (8.5%)	367	48 (12%)	353	41 (10.2%)	360
CACNA1G
(+)	80 (20%)	33 (97%)	47	38 (79%)	42	34 (83%)	46
(−)	321	1	320 (87%)	10	311 (88%)	7	314 (87%)
CDKN2A
(+)	231 (57.6%)	33 (97%)	198	38 (79%)	193	37 (90%)	194
(−)	170	1	169 (46%)	10	160 (45%)	4	166 (46%)
CRABP1
(+)	199 (49.6%)	34 (100%)	165	45 (94%)	154	40 (98%)	159
(−)	202	0	202 (55%)	3	199 (56%)	1	201 (56%)
IGF2
(+)	123 (30.7%)	24 (71%)	99	40 (83%)	83	34 (83%)	89
(−)	278	10	268 (73%)	8	270 (77%)	7	271 (75%)
MLH1
(+)	15 (3.7%)	5 (15%)	10	4 (8.3%)	11	4 (9.8%)	11
(−)	386	29	357 (97%)	44	342 (97%)	37	349 (97%)
NEUROG1
(+)	125 (31.2%)	33 (97%)	92	43 (90%)	82	39 (95%)	86
(−)	276	1	275 (74%)	5	271 (77%)	2	274 (76%)
RUNX3
(+)	29 (7.2%)	16 (47%)	13	27 (56%)	2	25 (61%)	4
(−)	372	18	354 (96%)	21	351 (99%)	16	356 (99%)
SOCS1
(+)	68 (17%)	13 (38%)	55	24 (50%)	44	19 (46%)	49
(−)	333	21	312 (85%)	24	309 (88%)	22	311 (86%)

^aSensitivity of each marker is defined as the number of CIMP-high cases positive for a given marker divided by the number of all CIMP-high cases
^bSpecificity of each marker is defined as the number of non-CIMP-high cases negative for a given marker divided by the number of all non-CIMP-high cases

ISSN: 1471-230X